AtriCure Appoints Robert S. White to its Board of Directors
AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems for the treatment of atrial
fibrillation, or AF, and systems for the exclusion of the left atrial
appendage, today announced that Robert “Bob” S. White has been appointed
to the Company’s Board of Directors, effective immediately.
Mr. White is a veteran in the medical technology industry with over 25
years of experience in commercial expansion, operations and sales. He is
currently President and CEO of TYRX, a privately-held company, which
commercializes innovative, implantable combination drug and device
products focused on infection control, including the AIGISRx®
Antibacterial Envelope, designed to reduce surgical site infections
associated with Cardiac Implantable Electronic Devices (CIEDs). Prior to
joining TYRX, Mr. White held several positions with Medtronic, Inc. Mr.
White served as President of Medtronic Kyphon following its $3.9 billion
acquisition of the spinal treatment business. During his time with
Medtronic, Mr. White also served as President of Physio Control and was
responsible for commercial operations of the Cardiac Rhythm Disease
Management business as Vice President of U.S. Sales and Global
Marketing. Earlier in his career, Mr. White held positions with General
Electric Company and Eli Lilly and Company among others. Mr. White holds
a MBA from Cornell University and a BS in Aerospace Engineering from the
University of Missouri-Rolla.
"Bob has significant leadership experience spanning operations, business
development and sales and marketing within the medical device industry,
and I believe he will bring significant value to AtriCure and its Board
of Directors," said Michael Carrel, President and CEO of AtriCure. “It
was immediately clear that Bob exceeded our collective criteria for a
board member as he is a seasoned executive with extensive experience
growing companies commercially. His experience managing and growing
several hundred million dollar divisions within Medtronic, and as the
current CEO of TYRX, will be incredibly valuable as we seek to further
penetrate the AF market. We are thrilled to have him on board.”
"I am pleased to be joining AtriCure, a company at its inflection point
in terms of growth and of making great progress in the treatment of
atrial fibrillation," said Mr. White. "I look forward to working with
the Board and the team at AtriCure to help execute on a solid strategy
to expand commercialization and further develop the current and future
pipeline."
About AtriCure, Inc.
AtriCure, Inc. is a medical device company providing innovative Atrial
Fibrillation (Afib) solutions designed to produce superior outcomes that
reduce the economic and social burden of Atrial Fibrillation. AtriCure’s
Synergy Ablation System is the first and only device approved for the
treatment of Persistent and Longstanding Persistent forms of Afib in
patients undergoing certain open concomitant procedures. AtriCure’s
AtriClip Left Atrial Appendage (LAA) exclusion device is the most widely
implanted device for LAA management worldwide. The company believes
cardiothoracic surgeons are adopting its ablation and LAA management
devices for the treatment of Afib and reduction of Afib related
complications such as stroke. Afib affects more than 5.5 million people
worldwide.
Forward-Looking Statements
This press release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements that address activities,
events or developments that AtriCure expects, believes or anticipates
will or may occur in the future, such as earnings estimates (including
projections and guidance), other predictions of financial performance,
launches by AtriCure of new products and market acceptance of AtriCure’s
products. Forward-looking statements are based on AtriCure’s experience
and perception of current conditions, trends, expected future
developments and other factors it believes are appropriate under the
circumstances and are subject to numerous risks and uncertainties, many
of which are beyond AtriCure’s control. These risks and uncertainties
include the rate and degree of market acceptance of AtriCure’s products,
AtriCure’s ability to develop and market new and enhanced products, the
timing of and ability to obtain and maintain regulatory clearances and
approvals for its products, the timing of and ability to obtain
reimbursement of procedures utilizing AtriCure’s products, competition
from existing and new products and procedures or AtriCure’s ability to
effectively react to other risks and uncertainties described from time
to time in AtriCure’s SEC filings, such as fluctuation of quarterly
financial results, reliance on third party manufacturers and suppliers,
litigation or other proceedings, government regulation and stock price
volatility. AtriCure does not guarantee any forward-looking statement,
and actual results may differ materially from those projected. AtriCure
undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or
otherwise. A further list and description of risks, uncertainties and
other matters can be found in our Annual Reports on Form 10-K and
Quarterly Reports on Form 10-Q.
